IJROBP - The Red Journal

First place prize: @IJROBP swag! @sueyom

Long-term results of NRG/RTOG 9601, a randomized trial of radiation with or without antiandrogens in patients receiving salvage prostate bed radiation therapy postprostatectomy, published in the #RedJournal. 👉 Read it before your patients: shorturl.at/fi0VZ @ASTRO_org

Check out our new #RedJournal Outtake from Drs. Sian Cooper and Steve Nicholson on Standardization of Radiation Therapy to Inguinal and Pelvic Lymph Nodes in Locally Advanced Cancer of the Penis, as Defined by the International Penile Advanced Cancer Trial (InPACT). #radonc tinyurl.com/scsnrjo

Our recently published #redjournal article is now available Open Access. Impact of Palliative Radiation Therapy on Quality of Life in Patients with Bone Versus Nonbone Lesions: Secondary Analysis of a Prospective Study doi.org/10.1016/j.ijro…

Health-related quality of life in patients treated for nonmetastatic muscle-invasive #bladdercancer: radical cystectomy versus bladder-preserving therapy, published in the #RedJournal. 👉 Read it before your patients: bit.ly/4pcHRyA @ASTRO_org

Efficacy of Stereotactic Ablative Body #Radiotherapy (#SABR) in uncommon subtypes of #kidneycancer, published in #RedJournal. 👉 Read it before your patients: bit.ly/49RNJIA @ASTRO_org

Read this #RedJournal article about a prospective phase 2 trial of renal SBRT demonstrating modest decline in renal function following treatment and excellent cancer control rates @r_glicksman @JA_Helou @UroOncMD @RHamiltonUrol @aleberlin2 @onconeph @radmedPM @UofTDRO @UHN_Research tinyurl.com/rjglicksman

HNSCCUP: Involved neck only RT results in low rates of primary site emergence and CLNF, reduced toxicity and no difference in OS compared to mucosal RT. 195 patients, largest series in HPV and FDG PET-CT era. Read about it in the #RedJournal @claire_paters0n @onctrainees @UofGMVLS tinyurl.com/patersonrj

Excited to share our Phase 2 trial results in the @RedJournal, investigating the combination of SBRT and pembrolizumab for patients with recurrent, or metastatic HNSCC that was refractory to prior PD-1 inhibitor treatment. HNSCC patients progressing on PD-1 inhibitors have poor prognoses. While many systemic therapies are under investigation, our data suggests that comprehensive SBRT+pembrolizumab is an effective strategy for patients with oligoprogression. Key Findings with comprehensive SBRT+pembro to all progressing lesions (Cohort B): 3-Month PFS: 67% (median PFS 5.7 months) OS: Median OS was 10.1 months. Safety: The approach was feasible and safe, even in the re-irradiation setting. Results with comprehensive SBRT in Cohort B were more favorable to Cohort A where only a single lesion was irradiated+pembro. Consistent with other studies, we did not observe abscopal responses. Huge credit to Jonathan So for leading the correlative analyses. Higher baseline CD8+ central memory T cells were correlated with treatment benefit - a starting point for deeper analyses currently ongoing. Full article here: doi.org/10.1016/j.ijro… #HNSCC #RadOnc #Immunotherapy #SBRT Figure 2: Kaplan-Meier analysis demonstrating more favorable PFS and OS for Cohort B (blue, comprehensive SBRT).

Helpful #NasopharynxCancer review now available in @RedJournal! #RadOnc #NPC #hncsm The latest on: 🔹 Treatment de-intensification 🔹 Immunotherapy intensification 🔹 Personalizing care with EBV DNA 🔹 Strategies for recurrent/metastatic disease Free access: authors.elsevier.com/c/1mPlt1Hx52Ny… Includes great figures summarizing 2024/2025 consensus guidelines for primary and nodal radiation oncology target volume delineation. 👇

This Brief Report in the #RedJournal highlights a real-time central review process for radiation therapy in the COG AHOD2131 trial for Hodgkin lymphoma. This article aims to improve treatment accuracy and protocol compliance in modern ISRT and pRSRT approaches. Read it here: tinyurl.com/rjlohoppe

New in the #RedJournal: Insights on personalized RT in rectal cancer. This ERI-based model integrates early tumor response and dose to guide adaptive treatment, improving pCR prediction and treatment individualization. #RadiationOncology #PrecisionMedicine #rectalcancer @Aleale______ tinyurl.com/rjcicchetti

In this #RedJournal article, chemotherapy followed by hypo-fractionated radiotherapy for surgically staged locally advanced endometrial cancer was safe in this early-phase trial. Further research is needed to evaluate whether this can become a standard of care option. @JoshSchiffMD @SilpaCRaju @WashUMedRadOnc tinyurl.com/rjjpschiff

New in the #RedJournal, this study reveals major global variation in how a “70 Gy” dose is prescribed for oropharyngeal cancer. 70 Gy is not always the same across centers, highlighting the need for harmonized standards to ensure consistent care & trial interpretation. #RadOnc #HNC tinyurl.com/rjcrhansen

New in the #RedJournal: Raaijmakers et al. show that radiation up to 68 Gy does not induce cell death, but senescence in patient-derived Cancer-Associated Fibroblasts (CAFs). The authors demonstrate that irradiated CAFs maintain pro-tumorigenic properties and can be targeted with senolytic drugs. tinyurl.com/rjktpmr

This #RedJournal article presents a first step towards continuous dosimetry in targeted radiopharmaceutical therapy by developing a sparse sensor system to reconstruct continuous time-activity curves in preclinical 177Lu-based therapies, demonstrating high accuracy with short scan times. tinyurl.com/rjlall

New from @Raquib_Hannan in the #RedJournal: One of the largest cohorts of oligoprogressive #RCC treated with #SAbR during systemic therapy. tinyurl.com/rjlzhao

No se lo pierdan número especial #redjournal #SBRT #radiocirugia con los expertos @ASTRO_org @IJROBP Y el podcast con el experto @drdavidpalma

IJROBP study: leveraging the helical TomoTherapy thread effect, an optimized hypofx approach achieved comparable modeled tumor control to conv fx, with shorter treatment courses, based on dosimetric and in vitro analyses. 🔗 doi.org/10.1016/j.ijro…

@jryckman3 @_ShankarSiva @drspdavid @e_emma243 One more similar approach, also recently out in @IJROBP, using partitioned survival analysis which builds on superimposed time-to-event curves: x.com/davidjeinstein…